Cognition Therapeutics
Edit

Cognition Therapeutics

http://www.cogrx.com/
Last activity: 14.03.2024
Categories: LifeLearnHomeFinTechTechnologyMedtechDevelopmentCauseBioTechDrug
Treating CentralNervous Systemdisorders by targeting the cellulardamage responsemechanism​​sTargeting key cellular response mechanisms to fight degenerative diseases. Neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies and age-related macular degeneration, involve different regions of the central nervous system, yet they share key defects in cellular pathways. By selectively modulating a central cellular damage response … Home Read More »
Followers
390
Mentions
52
Location: United States, New York, Town of Harrison
Employees: 11-50
Total raised: $182.24M
Founded date: 2007

Investors 11

Show more

Funding Rounds 8

DateSeriesAmountInvestors
14.03.2024-$11.5M-
11.01.2024Grant$3.3M-
11.01.2024Grant$75.8M-
09.06.2020Grant$75.8M-
11.09.2015Series B$12M-
11.10.2013-$138K-
20.01.2011-$2.5M-
16.07.2009-$1.2M-

Mentions in press and media 52

DateTitleDescriptionSource
14.03.2024Cognition Therapeutics Announces Closing of $11.5 Million Pu...-globenewsw...
13.03.2024Cognition Therapeutics Announces Public OfferingCognition Therapeutics, a company focused on treating neurodegenerative disorders, has priced a publ...parsers.vc...
12.03.2024Cognition Therapeutics Announces Pricing of $11.5 Million Pu...PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “C...einpresswi...
11.03.2024Cognition Therapeutics Announces Proposed Public Offering of...PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “...einpresswi...
11.03.2024Cognition Therapeutics Announces Proposed Public Offering of...-globenewsw...
11.03.2024Cognition Therapeutics Announces Pricing of $11.5 Million Pu...-globenewsw...
06.03.2024Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Corr...-globenewsw...
27.10.2023Cognition Therapeutics and Collaborators at Yale and ACTC An...NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced th...einpresswi...
04.05.2023Cognition Therapeutics Reports First Quarter 2023 Financial .../EIN News/ -- Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease ...einpresswi...
09.08.2022Cognition Therapeutics Reports Second Quarter 2022 Financial...Cognition Therapeutics reported on 2nd quarter financial results and business updates including opti...sofiafund....
Show more

Reviews 0

Sign up to leave a review

Sign up Log In